ADMA Biologics (ADMA) to Release Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) will post its quarterly earnings results on Thursday, February 22nd. Analysts expect ADMA Biologics to post earnings of ($0.33) per share for the quarter.

ADMA Biologics (ADMA) opened at $4.02 on Thursday. The firm has a market capitalization of $98.79, a PE ratio of -4.90 and a beta of 2.58. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics has a one year low of $2.01 and a one year high of $5.44.

A number of equities analysts have weighed in on the company. Maxim Group restated a “buy” rating and issued a $8.00 target price (down from $13.00) on shares of ADMA Biologics in a research note on Monday, December 11th. Raymond James Financial upgraded ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday, November 14th.

TRADEMARK VIOLATION NOTICE: “ADMA Biologics (ADMA) to Release Earnings on Thursday” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/15/adma-biologics-adma-to-release-earnings-on-thursday.html.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply